May Wang
Corporate Officer/Principal bei HUTCHMED (CHINA) LIMITED
Profil
Qing Mei Wang is currently working as the SVP-Business Development & Strategic Alliances at HUTCHMED (China) Ltd.
since 2010 and at Hutchison MediPharma Ltd.
since 2012.
Previously, Dr. Wang worked as the Head-Asia Discovery Biology at Eli Lilly & Co. Dr. Wang holds a doctorate degree from Purdue University.
Aktive Positionen von May Wang
| Unternehmen | Position | Beginn |
|---|---|---|
| HUTCHMED (CHINA) LIMITED | Corporate Officer/Principal | 01.01.2010 |
Hutchison MediPharma Ltd.
 Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Corporate Officer/Principal | 27.07.2011 |
Ehemalige bekannte Positionen von May Wang
| Unternehmen | Position | Ende |
|---|---|---|
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Ausbildung von May Wang
| Purdue University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| HUTCHMED (CHINA) LIMITED | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Hutchison MediPharma Ltd.
Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Health Technology |
